stockrow
Friday 6 November 2026
Export TRAX’s income statement to Excel — free account
First Tracks Biotherapeutics, Inc.
TRAX Healthcare Biotechnology
- EPS
- +40.5%
- Free cash flow
- +55.9%
Quarter to September 2026, against a year earlier
47.78
2.35
+5.17%
Follow TRAX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | 0.00% | 0.00% | 0.00% | |
| — | 0.00% | (183.64%) | 0.00% | ||
ROIC |
0.00% | 0.00% | (14,355.96%) | 0.00% | |
Return on Tangible Assets |
0.00% | (70.68%) | (101.08%) | (105.69%) | |
Free Cash Flow per Share |
— | 0.00 | (3.83) | (3.14) | |
Free Cash Flow |
— | (147.00) | (133.90) | (112.27) | |
Capital Expenditures |
— | (0.10) | (0.09) | (0.05) | |
| Other line items | |||||
Cash ROIC |
0.00% | (27.03%) | (39.75%) | (36.61%) | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
— | 0.81 | 0.80 | 0.71 | |
Depreciation/Fixed assets |
0.00 | (2.10) | (0.98) | 0.96 | |
Capex/Depreciation |
— | 0.04 | 0.09 | (0.06) | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
— | 0.00 | (3.82) | (3.14) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026